While it is clear that MAGI1 expression is reduced during cancer progression, it is not clear yet whether MAGI1 levels may be used to stratify cancer patients for prognostic purposes and, more importantly, for therapeutic decisions. The gene discussed is MAGI1; the disease is cancer.